The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal Allografts
Open accessAbstract
Interleukin-2 is a major growth factor for activated T lymphocytes, and antibodies reacting with the Tac-chain component of the interleukin-2 receptor can prevent allograft rejection in animals. Because Tac chains are expressed only on a small fraction of activated lymphocytes, monoclonal antibodies against the interleukin-2 receptor may offer a more specific means of immunosuppression than polyclonal antilymphocyte globulin in prophylaxis against graft rejection. Therefore, we compared the immunosuppressive effect of 33B3.1, a rat monoclonal antibody against the human Tac chain, with the effect of a rabbit polyclonal antithymocyte globulin in a randomized study of 100 recipients of first renal transplants. Injections of 33B3.1 (10 mg per day) were tolerated well, whereas major side effects in 15 of 47 patients (32 percent) receiving antithymocyte globulin required discontinuation of treatment before day 14. The incidence of rejection episodes was not statistically different in the two groups at days 14, 30, 60, and 90 after transplantation. Patient and graft survival was also equal in the two groups at one year (96 and 85 percent, respectively, in both groups), and graft function was similar. The total number of infectious episodes within the first three months was lower in the 33B3.1 group than in the antithymocyte group (47 vs. 72). The drop in peripheral-blood lymphocyte concentrations was significantly larger in the patients treated with antithymocyte globulin. The level of circulating Tac-chain-bearing lymphocytes remained below 1 percent during 33B3.1 treatment, as compared with 4 to 5 percent during antithymocyte-globulin treatment (P not significant). We conclude that 33B3.1 is as effective as antithymocyte globulin in the prevention of renal-transplant rejection, and its use results in fewer infections and side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uchiyama, T., Broder, S., & Waldmann, T. A. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.126.4.1393 · Cited by 1,329
T cell growth factor receptors. Quantitation, specificity, and biological relevance
Robb, R., Munck, A., & Smith, K. (1981) · The Journal of Experimental Medicine · doi:10.1084/jem.154.5.1455 · Cited by 1,061
Robb, R. J., Greene, W. C., & Rusk, C. M. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.4.1126 · Cited by 725
Novel Interleukin-2 Receptor Subunit Detected by Cross-Linking Under High-Affinity Conditions
Sharon, M., Klausner, R. D., Cullen, B. R., Chizzonite, R., & Leonard, W. J. (1986) · Science · doi:10.1126/science.3095922 · Cited by 572
Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.
Teshigawara, K., Wang, H. M., Kato, K., & Smith, K. A. (1987) · The Journal of experimental medicine · doi:10.1084/jem.165.1.223 · Cited by 548
Bacha, P., Williams, D. P., Waters, C., Williams, J. M., Murphy, J. R., & Strom, T. B. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.2.612 · Cited by 220
Kirkman, R. L., Barrett, L. V., Gaulton, G. N., Kelley, V. E., Ythier, A., & Strom, T. B. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.1.358 · Cited by 189
PREVENTION OF REJECTION OF KIDNEY TRANSPLANTS BY MONOCLONAL ANTIBODY DIRECTED AGAINST INTERLEUKIN 2
Soulillou, J., Mauff, B. L., Olive, D., DELAAGE, M. A., Peyronnet, P., Hourmant, M., Mawas, C. E., Hirn, M. H., & Jacques, Y. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90648-9 · Cited by 135
Self-citationONE-MONTH PROPHYLACTIC USE OF OKT3 IN CADAVER KIDNEY TRANSPLANT RECIPIENTS
Debure, A., Chkoff, N., Chatenoud, L., et al. (1988) · Transplantation · doi:10.1097/00007890-198803000-00009 · Cited by 102
Jacques, Y., Mauff, B. L., Boeffard, F., et al. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.7.2308 · Cited by 87
Self-citation
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 864
Nashan, B., Moore, R., Amlot, P., Schmidt, A.-G., Abeywickrama, K., & Soulillou, J.-P. (1997) · The Lancet · doi:10.1016/s0140-6736(97)09278-7 · Cited by 749
Self-citationDantal, J., Hourmant, M., Cantarovich, D., Giral, M., Blancho, G., Dreno, B., & Soulillou, J.-P. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08496-1 · Cited by 745
Self-citationKahan, B. D., Rajagopalan, P. R., & Hall, M. (1999) · Transplantation · doi:10.1097/00007890-199901270-00016 · Cited by 476
Metadata
- Authors
- Soulillou, J.-P., Cantarovich, D., Le Mauff, B., Giral, M., Robillard, N., Hourmant, M., Hirn, M., & Jacques, Y.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1990-04-26
- Volume
- 322
- Issue
- 17
- Pages
- 1175-1182
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2332754031
- Cited by
- 267
- References
- 13
- FWCI
- 21.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal Allografts. https://app.cochat.ai/papers/10.1056/nejm199004263221702
- The paper
- Soulillou, J.-P., Cantarovich, D., Le Mauff, B., Giral, M., Robillard, N., Hourmant, M., Hirn, M., & Jacques, Y. (1990). Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal Allografts. New England Journal of Medicine. https://doi.org/10.1056/nejm199004263221702
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.